Icariin alleviates rheumatoid arthritis via regulating miR-223-3p/NLRP3 signalling axis

• Published in: Autoimmunity (Chur, Switzerland) Vol. 53; no. 8; pp. 450 - 458
• Main Authors: Wu, Zhi-Ming, Luo, Jun, Shi, Xiao-Dong, Zhang, Shao-Xin, Zhu, Xiao-Bo, Guo, Jian
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 01.12.2020; Taylor & Francis Group
• Subjects: chronic autoimmune disease; Icariin; MiR-223-3p; NLRP3; rheumatoid arthritis; Icariin; NLRP3; MiR-223-3p; chronic autoimmune disease; rheumatoid arthritis
• ISSN: 0891-6934; 1607-842X; 1607-842X
• DOI: 10.1080/08916934.2020.1836488

Rheumatoid arthritis (RA) is considered to be a chronic autoimmune disease, pathogenesis of RA is complex and effective treatments for RA is still lacking. Previous studies found that microRNAs (miRNAs) play important roles in the pathogenesis of RA, and miR-223-3p is considered to be one of the possible biomarkers of RA. Recent studies have revealed that icariin alleviates RA in murine models, but the underlying mechanism needs to be further investigated. MiR-223-3p expression levels in fibroblast-like synoviocyte (RA-FLS) and patients with RA were quantified by qRT-PCR, cell proliferation was analyzed by CCK-8 and BrdU assay. Cell apoptosis was assessed by flow cytometry and western blotting. TNF-α, IL-1β and IL-6 concentrations were measured by enzyme-linked immunosorbent assay (ELISA). Dual luminescence-based reporter gene assay was conducted to confirm the possible interaction between miR-223-3p and NLRP3. Icariin inhibits proliferation and inflammation cytokines secretion, promotes apoptosis of RA-FLS cells and upregulated the expression of miR-223-3p. MiR-223-3p targets to 3'-UTR of NRLP3 and regulates its expression. MiR-223-3p inhibitor reversed the effect of icariin on RA-FLS cells function. Additionally, anti-RA activity of icariin was restored by NLRP3 inhibitor MCC950 in miR-223-3p knockdown RA-FLS cells. Icariin inhibits proliferation and inflammation, promotes apoptosis of RA-FLS cells by regulating miR-223-3p/NLRP3 signalling, which may serve as a potential therapeutic target to alleviate RA.